Affiliations 

  • 1 Leipzig, Germany
  • 2 Paris, France
  • 3 Shanghai, China
  • 4 Tianjin, China
  • 5 Pessac, France
  • 6 New Delhi, India
  • 7 Cluj-Napoca, Romania
  • 8 Seoul, Korea
  • 9 Rio de Janeiro, Brazil
  • 10 Pavia, Italy
  • 11 Kuala Lumpur, Malaysia
  • 12 Hong Kong, China
  • 13 Calgary, Canada
  • 14 Hiroshima, Japan
  • 15 Frankfurt, Germany
  • 16 Bondy, France
  • 17 Clichy, France
Aliment Pharmacol Ther, 2018 Apr;47(7):989-1000.
PMID: 29446106 DOI: 10.1111/apt.14529

Abstract

BACKGROUND: Liver fibrosis is often accompanied by steatosis, particularly in patients with non-alcoholic fatty liver disease (NAFLD), and its non-invasive characterisation is of utmost importance. Vibration-controlled transient elastography is the non-invasive method of choice; however, recent research suggests that steatosis may influence its diagnostic performance. Controlled Attenuation Parameter (CAP) added to transient elastography enables simultaneous assessment of steatosis and fibrosis.

AIM: To determine how to use CAP in interpreting liver stiffness measurements.

METHODS: This is a secondary analysis of data from an individual patient data meta-analysis on CAP. The main exclusion criteria for the current analysis were unknown aetiology, unreliable elastography measurement and data already used for the same research question. Aetiology-specific liver stiffness measurement cut-offs were determined and used to estimate positive and negative predictive values (PPV/NPV) with logistic regression as functions of CAP.

RESULTS: Two thousand and fifty eight patients fulfilled the inclusion criteria (37% women, 18% NAFLD/NASH, 42% HBV, 40% HCV, 51% significant fibrosis ≥ F2). Youden optimised cut-offs were only sufficient for ruling out cirrhosis (NPV of 98%). With sensitivity and specificity-optimised cut-offs, NPV for ruling out significant fibrosis was moderate (70%) and could be improved slightly through consideration of CAP. PPV for significant fibrosis and cirrhosis were 68% and 55% respectively, despite specificity-optimised cut-offs for cirrhosis.

CONCLUSIONS: Liver stiffness measurement values below aetiology-specific cut-offs are very useful for ruling out cirrhosis, and to a lesser extent for ruling out significant fibrosis. In the case of the latter, Controlled Attenuation Parameter can improve interpretation slightly. Even if cut-offs are very high, liver stiffness measurements are not very reliable for ruling in fibrosis or cirrhosis.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.